SILOSilo Pharma, Inc.

Nasdaq silopharma.com


$ 1.20 $ 0.00 (-0.17 %)    

Friday, 06-Sep-2024 15:57:50 EDT
QQQ $ 446.25 $ -12.35 (-2.68 %)
DIA $ 404.28 $ -3.99 (-0.98 %)
SPY $ 539.90 $ -9.25 (-1.68 %)
TLT $ 99.49 $ -0.01 (-0.01 %)
GLD $ 230.65 $ -1.72 (-0.74 %)
$ 1.198
$ 1.19 x 300
$ 1.20 x 100
-- - --
$ 0.84 - $ 4.50
69,687
na
5.37M
$ -13.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-25-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-24-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-01-2022 06-30-2022 10-Q
10 05-13-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-29-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 03-20-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-13-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 04-04-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-13-2018 06-30-2018 10-Q
26 05-15-2018 03-31-2018 10-Q
27 04-02-2018 12-31-2017 10-K
28 11-14-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-17-2017 03-31-2017 10-Q
31 03-31-2017 12-31-2016 10-K
32 10-28-2016 09-30-2016 10-Q
33 09-30-2016 06-30-2016 10-Q
34 08-31-2016 03-31-2016 10-Q
35 06-14-2016 12-31-2015 10-K
36 11-20-2015 09-30-2015 10-Q
37 08-14-2015 06-30-2015 10-Q
38 05-15-2015 03-31-2015 10-Q
39 03-31-2015 12-31-2014 10-K
40 11-14-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 silo-pharma-partners-with-global-cro-for-central-nervous-system-homing-peptide-shares-move-higher

The study will examine the organ/tissue specificity of the SPU-16 peptide in an experimental autoimmune encephalomyelitis (EAE)...

 silo-pharma-proposes-21m-registered-direct-offering-of-763638-shares-of-common-stock-at-a-purchase-price-of-275-per-share-priced-at-the-market-under-nasdaq-rules

Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focu...

 silo-pharma-finds-partner-for-device-development-for-intranasal-ptsd-drug

Silo Pharma stock soared on high trading volume after announcing a partnership with Resyca BV for developing an intranasal PTSD...

 why-is-nano-cap-silo-pharma-stock-skyrocketing-on-tuesday

Silo Pharma shares surge due to a global license agreement for Alzheimer's drug SPC-14, aiming to utilize the FDA's 505...

Core News & Articles
Market-Moving News for July 16th
07/16/2024 12:40:58

SILO: 143% | Silo Pharma Obtains Exclusive Global License To Develop, Manufacture, And Commercialize Its Alzheimer's Drug G...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION